Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery by Weber, Michel et al.
Recombinant Adeno-associated Virus Serotype 4
Mediates Unique and Exclusive Long-Term Transduction
of Retinal Pigmented Epithelium in Rat, Dog, and
Nonhuman Primate after Subretinal Delivery
Michel Weber,1,2 Joseph Rabinowitz,3 Nathalie Provost,1 Hervé Conrath,1,2
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We previously described chimeric recombinant adeno-associated virus (rAAV) vectors 2/4 and 2/5
as the most efficient vectors in rat retina. We now characterize these two vectors carrying the
CMV.gfp genome following subretinal injection in the Wistar rat, beagle dog, and cynomolgus
macaque. Both serotypes displayed stable GFP expression for the duration of the experiment (6
months) in all three animal models. Similar to the AAV-2 serotype, AAV-2/5 transduced both RPE
and photoreceptor cells, with higher level of transduction in photoreceptors, whereas rAAV-2/4
transduction was unambiguously restricted to RPE cells. This unique specificity found conserved
among all three species makes AAV-2/4-derived vectors attractive for retinal diseases originating
in RPE such as Leber congenital amaurosis (RPE65) or retinitis pigmentosa due to a mutated mertk
gene. To provide further important preclinical data, vector shedding was monitored by PCR in
various biological fluids for 2 months post-rAAV administration. Following rAAV-2/4 and -5
subretinal delivery in dogs (n  6) and in nonhuman primates (n  2), vector genome was found
in lacrymal and nasal fluids for up to 3–4 days and in the serum for up to 15–20 days. Overall,
these findings will have a practical impact on the development of future gene therapy trials of
retinal diseases.
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INTRODUCTION
Recombinant adeno-associated virus (rAAV)-2 vectors are
capable of efficient and prolonged transgene expression
in a number of tissues and have been used to deliver
therapeutic genes to correct defects in animal models of
various human disorders [1–8]. More recently, seven
other rAAV serotypes (AAV-1, -3, -4, -5, -6, -7, and -8) have
been isolated and cloned [9–14]. A number of in vivo
studies showed that these new serotypes displayed tissue
preference and, therefore, improved safety [9,15–18].
However, so far, none of the new serotypes was reported
to exhibit a cell-type restriction in a given organ with a
conserved tropism among mammalians including a non-
human primate. In the retina, following subretinal deliv-
ery, AAV-2 vectors transduced retinal pigmented epithe-
lium and photoreceptor cells [19–21] and were successful
in delivering ribozymes, photoreceptor genes, and neuro-
trophic factors in mice and rat models of retinal degener-
ation [22–26]. Visual function was restored in a canine
model of childhood blindness using a rAAV-2 carrying a
wtRPE65 gene, providing critical preclinical data support-
ing these vectors for human applications [27]. We and
others studied rAAV chimeric serotypes in which the vec-
tor is flanked by AAV-2 ITRs but encapsidated in an
AAV-1, -2, -3, -4, or -5 shell [28–30]. We showed that their
subretinal delivery resulted in a quantitative transgene
expression hierarchy with rAAV-4 and -5 capsids being
the most efficient.
The present study was designed to evaluate the rAAV-4
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serotype delivered in the subretinal space of the rat, the
dog, and a nonhuman primate. Comparative evaluation
with serotype 5 was done in rat and canine models. We
believe that rAAV-mediated gene transfer in the eye of
large animals is highly relevant with respect to future
clinical development as it is anatomically more similar to
the human eye than either the mouse or the rat counter-
part. Also, surgical procedures for vector delivery are sim-
ilar. Therefore, studying vector shedding in this context
provides additional important preclinical information.
RESULTS
Subretinal Delivery of rAAV-2/4.CMV.gfp and rAAV-
2/5.CMV.gfp in Rats
We performed subretinal injections of rAAV-2/4.CMV.gfp
and rAAV-2/5.CMV.gfp (4  1012 and 2  1012 vector
genome (vg)/ml corresponding to 8  109 and 4  109
vg/injection, respectively) on six Wistar rats (n  3 for
each serotype). As previously observed, fluorescent imag-
ing in live animals displayed a different pattern between
rAAV-2/4 and rAAV-2/5 [28], i.e., speckled GFP spots for
rAAV-2/4 (Fig. 1A), whereas rAAV-2/5 displayed in addi-
tion a uniform and homogeneous GFP signal (Fig. 1B). In
retina flat mounts, using a fluorescence inverted micro-
scope, rAAV-2/4-mediated gene expression was restricted
to the sclera/choroid/ retinal pigmented epithelium (RPE)
layer (Fig. 1C) and more specifically to RPE cells (Fig. 1G).
No signal was ever detected in the neuroretina layer (Figs.
1E and 1I). Conversely, rAAV-2/5-injected retina showed
GFP signal in both the sclera/choroid/RPE layer and the
neuroretina (Figs. 1D and 1F), namely, the RPE cells and
the photoreceptors (Figs. 1H and 1J).
Subretinal Delivery of rAAV-2/4.CMV.gfp and rAAV-
2/5.CMV.gfp in Dogs
We performed subretinal injection of rAAV-2/4.CMV.gfp
and rAAV-2/5.CMV.gfp via a transvitreal route within the
tapetal retina of six dogs (D1–D3 and D4–D6, respective-
ly). We chose the tapetal retina because RPE cells are not
pigmented in this region. D1 and D4 contralateral eyes
received saline injection (vehicle) alone. Retinas had all
flattened by 24 h postinjection (p.i.) and no inflammatory
response was detected by fundus photography (data not
shown). The transduced area seen by fluorescence exactly
matched the retinal detachment created by the injection
(Fig. 2). No fluorescence was detectable in the vehicle-
injected eyes (data not shown).
In rAAV-2/4.CMV.gfp animals, we detected weak GFP
expression first 15 days p.i. and it gradually increased to
reach a maximum level at 60 days (Figs. 2A, 2C, 2E, 2G,
and 2I). Conversely, in rAAV-2/5.CMV.gfp animals, GFP
expression was rapidly detected 3 days p.i. and then,
similar to rAAV-2/4.CMV.gfp, the signal gradually in-
creased to reach a maximum level at 60 days (Figs. 2B,
2D, 2F, 2H, and 2J). We monitored retinal morphology
and GFP expression in D1, D3, D4, and D6 by color
fundus photographs for up to 6 months and they showed
no abnormalities with a stable level of GFP expression
(data not shown).
Two months p.i., retina flat mounts were obtained
FIG. 1. Rat model. Rats were injected with rAAV-2/4.CMV.gfp (A, C, E, G, and
I) and rAAV-2/5.CMV.gfp (B, D, F, H, and J) and analyzed 30 days p.i. (A and
B) Fluorescence retinal imaging. (C and D) Sclera/choroid/RPE and (E and F)
neuroretina flat mounts. (G and H) Sections from sclera/choroid/RPE and (I
and J) neuroretina examined under an inverted fluorescence microscope. RPE,
retinal pigmented epithelium; ONL, outer nuclear layer; INL, inner nuclear
layer; GCL, ganglion cell layer.
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from D2 and D5 (rAAV-2/4 and rAAV-2/5, respectively).
Choroid/RPE layers were separated from the neuroretina
(Figs. 3A and 3B). Using an inverted fluorescence micro-
scope, we found the GFP signal to be restricted to the
choroid/RPE layer in D2 (Fig. 3C) and more specifically to
the RPE cells after flat-mount sectioning (Fig. 3E). Indeed,
no signal could be detected in the neuroretina (Figs. 3D
and 3F). Conversely in D5, GFP expression was detected
in both the choroid/RPE and the neuroretina flat mounts
(Figs. 3G and 3H), namely in RPE and in photoreceptors
(Figs. 3I and 3J). There was no RPE atrophy nor cellular
infiltration in both D2 and D5.
FIG. 3. Dog model. Flat mounts were obtained 2 months p.i. from two dogs:
D2 injected with rAAV-2/4.CMV.gfp (C, D, E, and F) and D5 with rAAV-2/
5.CMV.gfp (G, H, I, and J). Choroid/RPE (A) and neuroretina (B) layers were
separated. Choroid/RPE (C, E, G, and I) and neuroretina (D, F, H, and J) flat
mounts and sections were examined under an inverted fluorescence micro-
scope. See legend to Fig. 1 for RPE, ONL, INL, and GCL.
FIG. 2. Dog model. Live fluorescent retinal imaging at different time intervals
(3, 15, 30, and 60 days p.i.) in two dogs: D1 injected with rAAV-2/4.CMV.gfp
(A, C, E, G, and I) and D4 with rAAV-2/5.CMV.gfp (B, D, F, H, and J). ()
Retinal detachment created by the subretinal injection (A, B).
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As in rodents, the results demonstrated that an accu-
rate subretinal injection of rAAV-2/4 vector in dogs leads
to unique and exclusive transduction of RPE cells as op-
posed to the rAAV-2/5 vector for which transgene was
expressed both in RPE and in photoreceptor cells.
Subretinal Delivery of rAAV-2/4.CMV.gfp in
Nonhuman Primates
To test the tropism of the rAAV-2/4 vector in a relevant
preclinical animal model, we performed subretinal injec-
tion of 40 and 120 l of rAAV-2/4.CMV.gfp via a transvit-
real route in Mac1 and Mac2, resulting in retinal detach-
ment outside and within the macula, respectively (Fig. 4).
Similar to the canine model, the rAAV-2/4 vector resulted
in a detectable GFP signal 14 days p.i. in both animals
with a maximum expression level 60 days p.i. (Fig. 4).
While the GFP signal was homogeneous over the targeted
area in Mac1 (Figs. 4C, 4E, 4G, and 4I) Mac2 displayed a
less intense GFP signal within the macula (Figs. 4D, 4F,
4H, and 4J). Noticeably, compared with live fluorescence
imaging obtained in rAAV-2/4.CMV.gfp-treated dogs, the
GFP signal was less intense in both macaques. This result
is not surprising since in primates, RPE cells are strongly
pigmented resulting in partial fluorescence quenching.
We obtained retinal flat mounts from Mac2 65 days p.i.
During the dissection, the choroı̈d/RPE layer was sepa-
rated from the neuroretina. However, during this process,
pigmented RPE cells located between the two vascular
arcades did not detach easily from the neuroretina as
evidenced by the presence of RPE pigmentation on the
neuroretina (Figs. 4K and 4L). This technical handicap
was also observed on uninjected primate eyes and, there-
fore, was not attributed to the vector or the injection itself
(data not shown). As a consequence, GFP signal was ob-
served on both choroid/RPE and neuroretina flat mounts
(Figs. 4M and 4N). However, the GFP signal clearly dis-
played the typical hexagonal shape of RPE cells on both
flat mounts. We found no fine pixelized signal in the
neuroretina, suggesting that only RPE cells were actually
transduced. The signal observed in the neuroretina flat
mount could be due either to entire transduced RPE cells
or transduced RPE cell microvilli still attached to the
photoreceptor outer segments, or both. In support of this,
neuroretina sections displayed a pigmented layer that
corresponded to residual attached RPE microvilli (Fig. 5A).
The only detectable fluorescence signal in the neuroretina
was from transduced RPE microvilli (Fig. 5B) and no GFP
signal could be detected in the outer nuclear layer or in
the photoreceptor outer segments layer. Furthermore,
RPE cells were expressing GFP in the choroid/RPE layer
(Figs. 5C and 5D). As in rodents and dogs, our results
demonstrated that an accurate subretinal injection of
rAAV-2/4 vector in macaque led to unique and exclusive
transduction of RPE cells.
Vector Shedding after Subretinal Delivery of rAAV in
Dog and Nonhuman Primate
To provide additional preclinical data from large animal
models, we looked for vector shedding after rAAV delivery
in the subretinal space of dogs D1 through D6 and pri-
mates Mac1 and Mac2. We used PCR to detect rAAV
vector genome in several body fluids (Table 1). We first
evaluated the sensitivity of the assay by incubating a
known number of viral particles with saline before ex-
tracting the DNA as described [31]. The results indicated
that a threshold of 103 to 104 vg particles could be de-
tected (Fig. 6A). We collected serum, lacrymal, and nasal
samples from 15 min to 2 months p.i. and analyzed them
by PCR to detect the gfp DNA. Vector DNA could be
detected in the serum as soon as 15 min after rAAV ad-
ministration and up to 25 days in some instances (Fig. 6B
and Table 1). For lacrymal and nasal fluids, viral genome
was also detected as soon as 15 min and up to 4 days p.i.
(Fig. 6B and Table 1). Overall, the important finding is
that rAAV vector was shed in various biological fluids in
seven of eight large animals using a clinically relevant
surgical procedure and an accurate subretinal delivery
(Table 1).
DISCUSSION
This study showed that the type 4 AAV capsid allows
exclusive and stable transduction of RPE cells after sub-
retinal delivery, at least with a CMV-driven transgene.
This is a unique feature conserved among rodent, canine,
and nonhuman primate models. None of the other rAAV
serotypes provided such unambiguous specificity [28–30].
Therefore, rAAV-2/4 represents an important candidate
vector for therapy of RPE-specific genetic diseases such as
retinitis pigmentosa due to a mutated mertk gene [32] and
Leber congenital amaurosis [33,27]. In the mouse central
nervous system, rAAV-4 was also found to restrict trans-
gene expression to the ependymal cells [17]. This suggest
that RPE and ependymal cells may share a common re-
ceptor and/or coreceptor. Of note, a less efficient trans-
duction was obtained in the macula area of Mac2. This
unexplained observation suggested that additional pri-
mates are required to assess further the transduction effi-
ciency within the macula region.
The difference in the onset of transgene expression
between rAAV-2/4 (15 days) and rAAV-2/5 (3 days)
vector in the canine model might be due to only one cell
type (i.e., RPE) being transduced vs two (i.e., RPE and
photoreceptors). The GFP signal may have been higher
when both cell types expressed the transgene. An alterna-
tive explanation is that rAAV-2/5-mediated transduction
was more efficient and provided higher copy number per
diploid genome, resulting in faster transgene detection. In
any case, maximal transgene expression occurred 60
days p.i. in all dogs and macaques. This pattern is shared
by the nonchimeric AAV-2 vector [34–37], suggesting
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that it is linked to the AAV-2 ITR biology [38–40]. This
may be an advantage of the chimeric rAAV vectors over
the nonchimeric ones since the AAV-2 ITR-flanking vec-
tors are, so far, the most characterized in preclinical and
clinical trials [41,42].
Another important finding in the present study is the
discovery of shedding of the rAAV vector immediately
and up to several weeks after delivery using a clinically
relevant surgical approach. Shedding in lacrymal and na-
sal fluids was not unexpected because of the transvitreal
approach used. However, it remains difficult to explain
the presence of the vector in the serum for so long in
seven of eight animals. Whether it is possible that non-
infectious rAAV vectors trapped in the subretinal space
are slowly released to the highly vascularized choroı̈d
remains to be investigated. This finding is in contrast to
intramuscular delivery of rAAV-2 vectors of which detec-
tion in the sera lasted for only 2days p.i. in factor IX-
deficient patients [41] and for 6 days in nonhuman pri-
mates [31].
Overall, this study provides evidence that exclusive
targeting of the RPE cells is now possible using the rAAV-4
serotype in the rat, dog, and primate, making it an opti-
mal candidate for future clinical trials for Leber congenital
amaurosis. However, safety concerns are raised, which
will require additional long-term studies in large animal
models.
MATERIAL AND METHODS
rAAV-2/4 and rAAV-2/5 vectors. Recombinant AAV-2/4 and -2/5 vectors
carried a CMV.gfp genome flanked by AAV-2 ITRs encapsidated in an
AAV-4 and -5 shell, respectively. AAV-2/4 and AAV-2/5 vectors were pro-
duced as previously described [28,43]. The rAAV titers were determined by
dot blot and expressed as vector genome/ml [44]. They were 4  1012 and
2  1012 vg/ml for rAAV-2/4 and rAAV-2/5, respectively.
Subretinal injection. For rat, anesthesia, surgical procedures, and postsur-
gery care were performed as described previously [45]. Dogs and primates
were purchased from the Centre d’Elevage du Domaine des Souches,
Mezilles, and BioPrim, Baziège, France, respectively. All animals were cared
for in accordance with the ARVO statement for the use of animals in
ophthalmic and vision research. Subretinal injections were performed via
a transvitreal approach under isoflurane gas anesthesia. A 44-gauge can-
nula (Corneal) connected to a viscous fluid injection (VFI) system
(D.O.R.C. International, Netherlands) was used to deliver a controlled and
automated injection. The cannula was inserted through a sclerotomy and
advanced through the vitreous. Under microscopic control, virus solution
or vehicle alone (saline) was injected into the subretinal space underlying
the tapetal central retina by pressing the VFI system footswitch. Dogs 1 to
3 and 4 to 6 were injected subretinally with 60 to 100 l of rAAV-2/
4.CMV.gfp (4  1012 vg/ml) or rAAV-2/5.CMV.gfp (2  1012 vg/ml), re-
spectively, in the right eye. Postsurgical treatment included subcutaneous
FIG. 4. Nonhuman primate model. Live retinal fluorescence imaging at differ-
ent time intervals (14, 21, 35, and 60 days p.i.) in Mac 1 (A, C, E, G, and I) and
in Mac2 (B, D, F, H, and J). Both individuals received rAAV-2/4.CMV.gfp. ()
Retinal detachment created by the subretinal injection (A, B). Two months p.i.,
neuroretina (K, L, and N) and choroid/RPE (M) flat mounts were performed
and examined under inverted fluorescence microscope. M, macula; ONH,
optical nerve head; RV, retinal vessel.
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injections of Marbocyl (marbofloxacine; 20 mg in 0.2 ml) or Tolfedine
(tolferamic acid; 40 mg in 1 ml) and oral administration of Megasolone
(prednisolone; 10 mg) for 6 days postsurgery. A vitrectomy was performed
in two macaques—Mac1 and Mac2—before the subretinal injection of 40
and 120 l of rAAV-2/4.CMV.gfp, respectively.
In vivo GFP fluorescence imaging, retina flat mounting, and tissue sec-
tions. GFP expression in live rats, dogs, and primates was monitored at
weekly intervals by retinal fluorescence imaging as described [45]. The
sclera/choroid/RPE and neuroretina flat mounting was performed on 4%
paraformaldehyde-fixed enucleated eyes as previously described [45]. Tis-
sue sections were also made. For dogs and primates, RPE/choroid layers
were separated from the sclera.
Detection of rAAV vector DNA in body fluids after subretinal delivery in
dogs and macaques. Biological samples and PCR analyses were processed
as previously described [31]. The 5 primer (5-AAGTTCATCTGCAC-
CACCG-3) and the 3 primer (5-TGTTCTGCTGGTAGTGGTCG-3) were
both located in the gfp DNA sequence. PCR-amplified vector sequence
yielded a 424-bp fragment. After initial denaturation at 95°C for 5 min, 40
FIG. 5. Nonhuman primate model. Sections from neuroretina (A and B) and choroid/RPE (C and D) flat mounts were analyzed by either normal light microscope
(A and C) or inverted fluorescence microscope (B and D). See legend to Fig. 1 for RPE, ONL, INL, and GCL.
TABLE 1: Detection of rAAV vector sequences by PCR in body fluids
Serum Lacrymal Nasal Urine Feces
Dogs, AAV-2/5 D1 2–14 d 15 m–2 d 15 m–2 d n.d n.d
D2 2–19 d 15 m–1 d 2 d n.d n.d
D3 2–23 d 15 m–3 d 2 h–4 d n.d n.d
Dogs, AAV-2/4 D4 1–14 d 15 m–1 d 15 m–1 d n.d n.d
D5 2 h–14 d 15 m–2 d 2 h–1 d n.d n.d
D6 15 m–25 d 15 m–3 d 15 m–2 h n.d n.d
Mac, AAV-2/4 Mac1 2 h–16 d 15 m–2 h 15 m–2 h Negative Negative
Mac2 Negative 15 m–2 h Negative Negative Negative
d, days p.i.; h, hours p.i.; m, minutes p.i.; n.d, not done.
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cycles were run at 94°C for 30 s, 60°C for 30 s, 72°C for 30 s, followed by
incubation at 72°C for 10 min using Taq DNA polymerase (Promega) in a
Perkin–Elmer thermocycler (Perkin–Elmer, USA). Amplified products were
analyzed by agarose gel electrophoresis.
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